Gilead Sciences, Inc. today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the company's ...

Science communication, as a central element of public education ... an out-of-scope manuscript to a more suitable section or ...

Some of the newer AI-powered science search engines can already help people to produce narrative literature reviews — a ...

Gilead Sciences, Inc. today announced the presentation of new research data from its innovative HIV treatment portfolio and pipeline, including a broad range of data on investigational and marketed ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Nov. 4, 2024 — Using a sophisticated new modeling approach, researchers have estimated carbon dioxide emissions from inland waters to 22 million U.S. lakes, rivers ... Laser Measurements to ...

Professor Dietrich’s work has appeared in the Nature, American Political Science Review, Journal of Politics, Political Analysis, and Political Psychology. This work has also received grant support ...

UK High Court judge unconvinced by Pfizer that uniQure’s patent is invalid | Companies in dispute over patents covering ...

The EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting up a possible approval before year-end. Like Kite’s already-approved CAR-T ...

Here is set in one location — a piece of land in Pennsylvania — and seen through the perspective of a fixed camera over the course of more than 100 years. The relentless passage of time and ...

Watch an engaging conversation between ACS Central Science Editor-in-Chief Prof. Carolyn Bertozzi and C&EN Editor-in-Chief Nick Ishmael-Perkins, which took place at ACS Spring 2024, in New Orleans.